HOUSTON--(BUSINESS WIRE)--Saranas Inc., a medical device company with innovative technology for real-time detection and monitoring of internal bleeding during endovascular procedures, has been invited to present at the Transcatheter Valve Therapies (TVT) Structural Heart Disease Summit, which will take place June 20-23 at the Sheraton Grand Chicago. Scheduled presentations of interest include a moderated poster session by Philippe Généreux, MD, Saranas Chief Medical Officer and Co-Director of the Structural Heart Disease Program at Morristown Medical Center, Morristown, New Jersey, on Thursday, June 21 at 11:30 AM. Dr. Généreux will present results from the FDA-mandated validation study designed to assess the performance and safety of the Early Bird™ Bleed Monitoring System.
“Data from this robust animal study demonstrates the Early Bird’s efficacy in positively detecting the onset and progression of internal bleeds. As designed, the Early Bird System may protect, and in some cases, save the lives of patients undergoing an endovascular procedure by allowing physicians to detect the onset of bleeding early and to take appropriate steps to address the bleed before detrimental, irreversible, and life-threatening consequences occur,” stated Dr. Généreux.
An innovation presentation as part of the TVT Main Arena Day II on Friday, June 22 at 2 PM, will review the science of bioimpedance monitoring and the potential application of the Early Bird Bleed Monitoring System during endovascular procedures. Also, on Friday, June 22 at 12 PM, Saranas, Inc. is supporting the Lunch Satellite Program: Optimization of Vessel Access and Closure in Large Bore Catheter Procedure Tips and Tricks Case-Based Review.
President and CEO Zaffer Syed said, “We are excited to showcase the Early Bird System and to report the latest study data at TVT. We believe the Early Bird System may significantly reduce bleeding complications and improve clinical outcomes in patients undergoing endovascular procedures.”
The Early Bird Bleed Monitoring System includes a vascular access sheath with embedded sensors that are designed to detect and monitor bleeding from a blood vessel accidentally injured during endovascular procedures, such as a transcatheter aortic valve replacement (TAVR), large bore hemodynamic support device placement, or other complex cardiovascular interventions, where the femoral artery or vein is used to obtain vascular access. The technology was invented at the Texas Heart Institute.
Saranas is a privately held Houston-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s patented bleed monitoring system for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs. For more information, visit www.saranas.com.